{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:20:38Z","timestamp":1790349638748,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118635","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:16:55Z","timestamp":1770164215000},"page":"118635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discovery of KRAS-G12D degraders via exploration of various E3 ligases"],"prefix":"10.1016","volume":"307","author":[{"given":"Hyerin","family":"Yim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ejmech.2026.118635_bib1","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118635_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118635_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118635_bib4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41587-025-02592-1","article-title":"Induced proximity at the cell surface","volume":"43","author":"Till","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"46","key":"10.1016\/j.ejmech.2026.118635_bib5","doi-asserted-by":"crossref","first-page":"11463","DOI":"10.1002\/anie.201206231","article-title":"Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1\u03b1","volume":"51","author":"Buckley","year":"2012","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"6241","key":"10.1016\/j.ejmech.2026.118635_bib6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"D1","key":"10.1016\/j.ejmech.2026.118635_bib7","doi-asserted-by":"crossref","first-page":"D719","DOI":"10.1093\/nar\/gkab962","article-title":"UbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase\/deubiquitinase-substrate interactions in eukaryotic species","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118635_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118635_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrd1199","article-title":"HIF-1 as a target for drug development","volume":"2","author":"Giaccia","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118635_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jmcb\/mjy085","article-title":"DCAF1 (VprBP): emerging physiological roles for a unique dual-service E3 ubiquitin ligase substrate receptor","volume":"11","author":"Schabla","year":"2019","journal-title":"J. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118635_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41467-023-44237-4","article-title":"DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance","volume":"15","author":"Schr\u00f6der","year":"2024","journal-title":"Nat. Commun."},{"issue":"8009","key":"10.1016\/j.ejmech.2026.118635_bib12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41586-024-07224-3","article-title":"Proteome-scale discovery of protein degradation and stabilization effectors","volume":"628","author":"Poirson","year":"2024","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118635_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.chembiol.2023.07.006","article-title":"Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, \u03b2-catenin, and FoxP3","volume":"30","author":"R\u00f6th","year":"2023","journal-title":"Cell Chem. Biol."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118635_bib14","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","article-title":"Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of Androgen receptor for the treatment of prostate cancer","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118635_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor Target Antitumor Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118635_bib16","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1021\/acsmedchemlett.1c00298","article-title":"Rational control of molecular properties is mandatory to exploit the potential of PROTACs as oral drugs","volume":"12","author":"Ermondi","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118635_bib17","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118635_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamaoncol.2016.0405","article-title":"Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review","volume":"2","author":"Wood","year":"2016","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118635_bib19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"7477","key":"10.1016\/j.ejmech.2026.118635_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118635_bib21","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118635_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRAS(G12D)","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6715","key":"10.1016\/j.ejmech.2026.118635_bib23","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118635_bib24","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1021\/acs.jmedchem.5c00428","article-title":"Discovery and characterization of RP03707: a highly potent and selective KRAS(G12D) PROTAC","volume":"68","author":"Ji","year":"2025","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118635_bib25","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ccell.2025.07.006","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers","volume":"43","author":"Feng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118635_bib26","article-title":"Development of highly potent and selective oncogenic KRASG12D PROTAC degraders","volume":"15","author":"Mao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"45","key":"10.1016\/j.ejmech.2026.118635_bib27","doi-asserted-by":"crossref","first-page":"41367","DOI":"10.1021\/jacs.5c10354","article-title":"Identification of a highly cooperative PROTAC degrader targeting GTP-loaded KRAS(On) alleles","volume":"147","author":"Vetma","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118635_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118635_bib29","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1021\/acs.jmedchem.2c01721","article-title":"Degradation of Rat Sarcoma proteins targeting the post-translational prenyl modifications via cascade azidation\/fluorination and click reaction","volume":"66","author":"Zhou","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118635_bib30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","article-title":"Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)","volume":"151","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118635_bib31","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1021\/acs.jmedchem.0c01609","article-title":"Potent and selective mitogen-activated protein kinase kinase 1\/2 (MEK1\/2) heterobifunctional small-molecule degraders","volume":"63","author":"Hu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2026.118635_bib32","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.118635_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111952","article-title":"Development of selective mono or dual PROTAC degrader probe of CDK isoforms","volume":"187","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"613","key":"10.1016\/j.ejmech.2026.118635_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj1578","article-title":"A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models","volume":"13","author":"Yu","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118635_bib35","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1021\/acs.jmedchem.2c00345","article-title":"Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118635_bib36","doi-asserted-by":"crossref","first-page":"15627","DOI":"10.1021\/acs.jmedchem.2c00756","article-title":"Development and utility of a PAK1-selective degrader","volume":"65","author":"Chow","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118635_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the Cancer Dependency Map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118635_bib38","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1021\/acs.jmedchem.3c02203","article-title":"Potency-enhanced peptidomimetic VHL ligands with improved oral bioavailability","volume":"67","author":"Wu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8071","key":"10.1016\/j.ejmech.2026.118635_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","article-title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity","volume":"643","author":"Zhou","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118635_bib40","series-title":"Tetrahydroisoquinoline Heterobifunctional bcl-xl Degraders","author":"Horn","year":"2023"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118635_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41594-023-01146-w","article-title":"Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules","volume":"31","author":"Hickey","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118635_bib42","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.chembiol.2023.07.008","article-title":"Targeted kinase degradation via the KLHDC2 ubiquitin E3 ligase","volume":"30","author":"Kim","year":"2023","journal-title":"Cell Chem. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118635_bib43","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1021\/acs.jmedchem.2c02132","article-title":"Discovery of nanomolar DCAF1 small molecule ligands","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118635_bib44","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1021\/acsmedchemlett.3c00104","article-title":"Discovery of new binders for DCAF1, an emerging ligase target in the targeted protein degradation field","volume":"14","author":"Vulpetti","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"40","key":"10.1016\/j.ejmech.2026.118635_bib45","doi-asserted-by":"crossref","first-page":"18688","DOI":"10.1021\/jacs.2c08964","article-title":"Targeted protein degradation by electrophilic PROTACs that stereoselectively and site-specifically engage DCAF1","volume":"144","author":"Tao","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118635_bib46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.molcel.2018.04.006","article-title":"C-terminal end-directed protein elimination by CRL2 ubiquitin ligases","volume":"70","author":"Lin","year":"2018","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118635_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54500-x","article-title":"Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity","volume":"15","author":"Mabanglo","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118635_bib48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118635_bib49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118635_bib50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118635_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"6220","key":"10.1016\/j.ejmech.2026.118635_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118635_bib53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118635_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring targeted degradation strategy for oncogenic KRAS(G12C)","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell Chem. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:40:38Z","timestamp":1775482838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":54,"alternative-id":["S0223523426000802"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118635","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of KRAS-G12D degraders via exploration of various E3 ligases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118635"}}